Systematic review and meta‐analysis of Alzheimer’s disease clinical trial results over more than a quarter century (1994‐2025) ‐ overall evidence and time savings

Abstract

Background: Alzheimer’s disease (AD) trials led to recent successes with monoclonal antibodies targeting amyloid, opening up new directions for research into treatment for AD. Greater understanding of AD successes and failures will help researchers focus their efforts on the highest potential benefit, including combination treatments.

The paper